[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"case:lead-pharma-medicine-bv-09172969:header:guest:personal:":3,"case:lead-pharma-medicine-bv-09172969:investigations:guest:personal::{}":80},{"id":4,"slug":5,"name":6,"trade_names":7,"status":8,"procedure":9,"procedure_type":10,"insolvency_number":29,"case_number":29,"declared_on":30,"terminated_on":31,"termination_reason":32,"kvk_number":33,"legal_form":34,"sbi":14,"court":37,"judge":40,"judge_source":41,"curator":42,"location":46,"counts":56,"pages":61,"follower_count":60,"report_count":57,"last_report_on":73,"last_update_at":74,"freshness":75,"linked":79},"01M3SJFSJCWBFFNRZ7ERDWZQ0C","lead-pharma-medicine-bv-09172969","Lead Pharma Medicine B.V.",[],"terminated","bankruptcy",{"id":11,"key":9,"family":12,"name":13,"short_name":14,"legal_basis":15,"features":19},"01M3Y8CPCPT53NPXHK39BWK1QY","insolvency","Faillissement",null,{"name":16,"provision":17,"url":18},"Faillissementswet","Titel I (art. 1 e.v.)","https:\u002F\u002Fwetten.overheid.nl\u002FBWBR0001860",[20,21,22,23,24,25,26,27,28],"reports","financials","creditors","assets","investigations","curator_workspace","appointments","court_decisions","portfolio_monitoring","F.01\u002F25\u002F159","2025-06-17","2026-09-29","lack_of_assets","09172969",{"value":35,"source":36},"BV","cir",{"name":38,"slug":39,"location":14},"Rechtbank Oost-Brabant","oost-brabant","mr. S.C.E.F. Moulen Janssen",{"type":36,"report_number":14,"published_on":14},{"name":43,"slug":44,"law_firm":14,"city":14,"verified":45},"mr. D.P. Schalken","dp-schalken",false,{"street":47,"house_number":48,"addition":49,"postal_code":50,"city":51,"municipality":51,"province":52,"lat":53,"lng":54,"kind":55,"source":36},"Kloosterstraat","9","RK","5349AB","Oss","Noord-Brabant",51.760717,5.533719,"business",{"reports":57,"documents":58,"assets":59,"investigations":60,"news":60},9,13,6,0,{"overview":62,"reports":64,"financials":65,"investigations":66,"assets":67,"timeline":68,"documents":69,"news":70,"company":71,"compare":72},{"index":63,"ads":63},true,{"index":63,"ads":63},{"index":63,"ads":63},{"index":45,"ads":45},{"index":63,"ads":45},{"index":45,"ads":45},{"index":45,"ads":45},{"index":45,"ads":45},{"index":45,"ads":45},{"index":45,"ads":45},"2026-08-11","2026-10-04T17:34:33+00:00",{"last_checked_at":76,"last_reconciled_at":77,"stale":45,"status":78},"2026-10-08T18:00:16+00:00","2026-10-01T14:27:10+00:00","current",{"continued_from":14,"continued_as":14},{"data":81,"meta":250},[82,120,138,153,173,191,208,220,232],{"topic":83,"state":84,"category":85,"states":86,"source":106},"legality_review","mentioned","automated",[87,91,93,96,97,100,101,104,105],{"report_number":88,"report_date":89,"state":90},1,"2025-07-14","not_mentioned",{"report_number":88,"report_date":89,"state":92},"investigating",{"report_number":94,"report_date":95,"state":92},2,"2025-10-14",{"report_number":94,"report_date":95,"state":90},{"report_number":98,"report_date":99,"state":92},3,"2026-01-14",{"report_number":98,"report_date":99,"state":90},{"report_number":102,"report_date":103,"state":90},4,"2026-04-08",{"report_number":102,"report_date":103,"state":84},{"report_number":14,"report_date":73,"state":90},{"id":107,"category":85,"method":108,"source_type":109,"document":110,"page":115,"section":116,"excerpt":117,"certainty":118,"curator_verified_at":14,"processed_at":119},318138,"deterministic","cir_report",{"id":111,"title":112,"report_number":102,"report_date":103,"published_on":103,"page_count":113,"url":114,"available":63},"01M3SJG6EV72GZJ4NWXZ6V4RQB","Verslag: 08-04-2026",17,"https:\u002F\u002Ffaillissement.app\u002Fdocuments\u002F01M3SJG6EV72GZJ4NWXZ6V4RQB.pdf",11,"7.1 Boekhoudplicht","Voldaan.",0.5,"2026-10-02T18:43:03+00:00",{"topic":121,"state":84,"category":85,"states":122,"source":132},"director_liability",[123,124,125,126,127,128,129,130,131],{"report_number":88,"report_date":89,"state":90},{"report_number":88,"report_date":89,"state":92},{"report_number":94,"report_date":95,"state":92},{"report_number":94,"report_date":95,"state":90},{"report_number":98,"report_date":99,"state":92},{"report_number":98,"report_date":99,"state":90},{"report_number":102,"report_date":103,"state":90},{"report_number":102,"report_date":103,"state":84},{"report_number":14,"report_date":73,"state":90},{"id":133,"category":85,"method":108,"source_type":109,"document":134,"page":135,"section":136,"excerpt":137,"certainty":118,"curator_verified_at":14,"processed_at":119},318136,{"id":111,"title":112,"report_number":102,"report_date":103,"published_on":103,"page_count":113,"url":114,"available":63},12,"7.5 Onbehoorlijk bestuur","Toelichting Er is geen sprake van onbehoorlijk bestuur. De gemaakte intercompany-afspraken over de toebedeling van kosten en activa binnen het concern w erd achterhaald door het uitgesproken faillissement van Lead Pharma Holding B.V.",{"topic":139,"state":84,"category":85,"states":140,"source":150},"bookkeeping_duty",[141,142,143,144,145,146,147,148,149],{"report_number":88,"report_date":89,"state":90},{"report_number":88,"report_date":89,"state":92},{"report_number":94,"report_date":95,"state":92},{"report_number":94,"report_date":95,"state":90},{"report_number":98,"report_date":99,"state":92},{"report_number":98,"report_date":99,"state":90},{"report_number":102,"report_date":103,"state":90},{"report_number":102,"report_date":103,"state":84},{"report_number":14,"report_date":73,"state":90},{"id":151,"category":85,"method":108,"source_type":109,"document":152,"page":115,"section":116,"excerpt":117,"certainty":118,"curator_verified_at":14,"processed_at":119},318135,{"id":111,"title":112,"report_number":102,"report_date":103,"published_on":103,"page_count":113,"url":114,"available":63},{"topic":154,"state":155,"category":85,"states":156,"source":166},"annual_accounts_filing","completed",[157,158,159,160,161,162,163,164,165],{"report_number":88,"report_date":89,"state":90},{"report_number":88,"report_date":89,"state":155},{"report_number":94,"report_date":95,"state":155},{"report_number":94,"report_date":95,"state":90},{"report_number":98,"report_date":99,"state":155},{"report_number":98,"report_date":99,"state":90},{"report_number":102,"report_date":103,"state":90},{"report_number":102,"report_date":103,"state":155},{"report_number":14,"report_date":73,"state":90},{"id":167,"category":85,"method":108,"source_type":109,"document":168,"page":135,"section":169,"excerpt":170,"certainty":171,"curator_verified_at":14,"processed_at":172},134817,{"id":111,"title":112,"report_number":102,"report_date":103,"published_on":103,"page_count":113,"url":114,"available":63},"7.2 Depot jaarrekeningen","De jaarrekening 2023 is gedeponeerd op 4 juli 2024.",0.7,"2026-09-30T16:31:29+00:00",{"topic":174,"state":155,"category":85,"states":175,"source":185},"causes_investigation",[176,177,178,179,180,181,182,183,184],{"report_number":88,"report_date":89,"state":90},{"report_number":88,"report_date":89,"state":155},{"report_number":94,"report_date":95,"state":155},{"report_number":94,"report_date":95,"state":90},{"report_number":98,"report_date":99,"state":84},{"report_number":98,"report_date":99,"state":90},{"report_number":102,"report_date":103,"state":90},{"report_number":102,"report_date":103,"state":155},{"report_number":14,"report_date":73,"state":90},{"id":186,"category":85,"method":108,"source_type":109,"document":187,"page":188,"section":189,"excerpt":190,"certainty":171,"curator_verified_at":14,"processed_at":172},134802,{"id":111,"title":112,"report_number":102,"report_date":103,"published_on":103,"page_count":113,"url":114,"available":63},5,"1.5 Oorzaak faillissement","Tot heden is de curator het volgende gebleken uit gesprekken met het bestuur en betrokkenen, maar dit vormt geen conclusie. Lead Pharma Medicine B.V. exploiteert een farmaceutisch onderzoeks- en ontw ikkelbedrijf. Daartoe verricht zij onderzoek naar nieuw e medicijnen ter genezing van kanker en auto-immuunziekten. Medicijnonderzoek is een langdurig en kostbaar traject. Van een idee naar verkoop du",{"topic":192,"state":84,"category":85,"states":193,"source":203},"paulianas",[194,195,196,197,198,199,200,201,202],{"report_number":88,"report_date":89,"state":90},{"report_number":88,"report_date":89,"state":92},{"report_number":94,"report_date":95,"state":92},{"report_number":94,"report_date":95,"state":90},{"report_number":98,"report_date":99,"state":92},{"report_number":98,"report_date":99,"state":90},{"report_number":102,"report_date":103,"state":90},{"report_number":102,"report_date":103,"state":84},{"report_number":14,"report_date":73,"state":90},{"id":204,"category":85,"method":108,"source_type":109,"document":205,"page":135,"section":206,"excerpt":207,"certainty":118,"curator_verified_at":14,"processed_at":119},318137,{"id":111,"title":112,"report_number":102,"report_date":103,"published_on":103,"page_count":113,"url":114,"available":63},"7.6 Paulianeus handelen","Nee Toelichting Er is geen sprake van paulianeus handelen.",{"topic":209,"state":90,"category":14,"states":210,"source":14},"related_party_transactions",[211,212,213,214,215,216,217,218,219],{"report_number":88,"report_date":89,"state":90},{"report_number":88,"report_date":89,"state":90},{"report_number":94,"report_date":95,"state":90},{"report_number":94,"report_date":95,"state":90},{"report_number":98,"report_date":99,"state":90},{"report_number":98,"report_date":99,"state":90},{"report_number":102,"report_date":103,"state":90},{"report_number":102,"report_date":103,"state":90},{"report_number":14,"report_date":73,"state":90},{"topic":221,"state":90,"category":14,"states":222,"source":14},"fraud_report",[223,224,225,226,227,228,229,230,231],{"report_number":88,"report_date":89,"state":90},{"report_number":88,"report_date":89,"state":90},{"report_number":94,"report_date":95,"state":90},{"report_number":94,"report_date":95,"state":90},{"report_number":98,"report_date":99,"state":90},{"report_number":98,"report_date":99,"state":90},{"report_number":102,"report_date":103,"state":90},{"report_number":102,"report_date":103,"state":90},{"report_number":14,"report_date":73,"state":90},{"topic":233,"state":84,"category":85,"states":234,"source":244},"proceedings",[235,236,237,238,239,240,241,242,243],{"report_number":88,"report_date":89,"state":90},{"report_number":88,"report_date":89,"state":84},{"report_number":94,"report_date":95,"state":84},{"report_number":94,"report_date":95,"state":90},{"report_number":98,"report_date":99,"state":84},{"report_number":98,"report_date":99,"state":90},{"report_number":102,"report_date":103,"state":90},{"report_number":102,"report_date":103,"state":84},{"report_number":14,"report_date":73,"state":90},{"id":245,"category":85,"method":108,"source_type":109,"document":246,"page":247,"section":248,"excerpt":249,"certainty":118,"curator_verified_at":14,"processed_at":172},134820,{"id":111,"title":112,"report_number":102,"report_date":103,"published_on":103,"page_count":113,"url":114,"available":63},16,"9.1 Naam wederpartijen","Er is niet gebleken van procedures.",{"reports":251},[252,253,254,255,256,257,258,259,260],{"number":88,"published_on":89},{"number":88,"published_on":89},{"number":94,"published_on":95},{"number":94,"published_on":95},{"number":98,"published_on":99},{"number":98,"published_on":99},{"number":102,"published_on":103},{"number":102,"published_on":103},{"number":14,"published_on":73}]